pISSN 2234-3806eISSN 2234-3814
Fig. 4.
Kaplan–Meier survival curves for residual ctDNA and CA19-9 level changes post-chemotherapy. (A) Progression-free survival (PFS) for ctDNA non-responders, responders, and negatives. (B) Overall survival (OS) in the aforementioned groups. (C) PFS based on CA19-9 level reduction: <50%, ≥50%, and baseline <37 U/mL. (D) OS for the respective CA19-9 groups.
Ann Lab Med 2025;45:199~208 https://doi.org/10.3343/alm.2024.0345
© Ann Lab Med